<link rel="stylesheet" href="css/cards.css">
<div style="margin-top: 40px;margin-left:5%;margin-right:5%;">

    <nav aria-label="breadcrumb">
        <ol class="breadcrumb">
            <li class="breadcrumb-item"><a href="index.html">Home</a></li>
            <li class="breadcrumb-item">Pain</li>
            <li class="breadcrumb-item active" aria-current="page">Management</li>
        </ol>
    </nav>


    <div class="mainContent">
        <h2>Drugs</h2>
        <br>
        <ul class="nav nav-tabs" id="agitationManagementTab" role="tablist">
            <li class="nav-item">
                <a class="nav-link active" id="NSAIDs-tab" data-toggle="tab" href="#NSAIDs" role="tab"
                    aria-controls="NSAIDs" aria-selected="true">NSAIDs</a>
            </li>
            <li class="nav-item">
                <a class="nav-link" id="opioids-tab" data-toggle="tab" href="#opioids" role="tab"
                    aria-controls="opioids" aria-selected="false">Opioids</a>
            </li>
            <li class="nav-item">
                <a class="nav-link" id="others-tab" data-toggle="tab" href="#others" role="tab" aria-controls="others"
                    aria-selected="false">Others</a>
            </li>
        </ul>
        <div class="tab-content" id="agitationManagementTabContent">
            <div class="tab-pane fade show active" id="NSAIDs" role="tabpanel" aria-labelledby="NSAIDs-tab">
                <div class="mainContent">
                    <ul class="nav nav-pills mb-3" id="pills-tab-NSAIDs" role="tablist">
                        <li class="nav-item">
                            <a class="nav-link active" id="pills-diclofenac-tab" data-toggle="pill"
                                href="#pills-diclofenac" role="tab" aria-controls="pills-diclofenac"
                                aria-selected="true">Diclofenac</a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" id="pills-ketorolac-tab" data-toggle="pill" href="#pills-ketorolac"
                                role="tab" aria-controls="pills-ketorolac" aria-selected="false">Ketorolac</a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" id="pills-meloxicam-tab" data-toggle="pill" href="#pills-meloxicam"
                                role="tab" aria-controls="pills-meloxicam" aria-selected="false">Meloxicam</a>
                        </li>
                    </ul>
                    <div class="tab-content" id="pills-tab-NSAIDsContent">
                        <div class="tab-pane fade show active" id="pills-diclofenac" role="tabpanel"
                            aria-labelledby="pills-diclofenac-tab">
                            <div id="diclofenac">
                                <div class="card">

                                    <a class="collapsed" data-toggle="collapse" href="#diclofenacCollapseOne"
                                        role="button" aria-expanded="false" aria-controls="diclofenacCollapseOne">
                                        <div class="card-header" id="diclofenacheadingOne">
                                            <h1 class="card-heading">
                                                Dose
                                            </h1>
                                        </div>
                                    </a>
                                    <div id="diclofenacCollapseOne" class="collapse"
                                        aria-labelledby="diclofenacheadingOne" data-parent="#diclofenac">
                                        <div class="card-body">
                                            <p class="card-p">

                                                <b>Oral:</b> Extended-release tablet: 50 mg 3 times daily; may
                                                administer 100 mg as an initial
                                                dose,
                                                followed by 50 mg 3 times daily. <br>
                                                (Available formulations: 50-75-150 mg) <br>
                                                <b>-IV:</b> Voltaren 37.5 mg every 6 hours as needed; adjust frequency
                                                according to patient
                                                response (maximum: 150 mg/day). <br>

                                                <h4>- Max: </h4>150 mg/day IV……. 200 mg/day PO <br><br>
                                                <h4>- Hepatic: </h4>
                                                <b>Oral:</b>
                                                Use with caution; patients with hepatic disease may require reduced
                                                doses; start at the lowest
                                                dose, if efficacy is not achieved, consider drug discontinuation. <br>

                                                <b>Parenteral:</b>
                                                Mild hepatic impairment: No dosage adjustment recommended
                                                Moderate to severe hepatic impairment: Use is not recommended <br><br>
                                                <h4>- Renal: </h4>
                                                <b>Oral:</b> <br>
                                                Use with caution in patients with advanced renal disease; if treatment
                                                is initiated, close
                                                monitoring of renal function is recommended. <br>

                                                <b>Parenteral:</b><br>
                                                Moderate to severe renal insufficiency in the perioperative period and
                                                at risk for volume <br>
                                                depletion: Use is contraindicated <br>
                                                Moderate to severe renal impairment: Use is not recommended

                                            </p>
                                        </div>
                                    </div>
                                </div>
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#diclofenacCollapseTwo"
                                        role="button" aria-expanded="false" aria-controls="diclofenacCollapseTwo">
                                        <div class="card-header" id="diclofenacheadingTwo">
                                            <h1 class="card-heading">Warnings</h1>
                                        </div>
                                    </a>
                                    <div id="diclofenacCollapseTwo" class="collapse"
                                        aria-labelledby="diclofenacheadingTwo" data-parent="#diclofenac">
                                        <div class="card-body">
                                            <ol>
                                                <li>
                                                    Transaminase elevations have been reported with use; closely monitor
                                                    patients with any
                                                    abnormal LFT.
                                                </li>
                                                <li>
                                                    [US Boxed Warning]: NSAIDs cause an increased risk of serious (and
                                                    potentially fatal)
                                                    adverse cardiovascular thrombotic events, including MI and stroke.
                                                    Risk may occur early
                                                    during treatment and may increase with duration of use.
                                                </li>
                                                <li>
                                                    [US Boxed Warning]: NSAIDs cause an increased risk of serious
                                                    gastrointestinal inflammation,
                                                    ulceration, bleeding, and perforation (may be fata); elderly
                                                    patients and patients with
                                                    history of peptic ulcer disease and/or GI bleeding are at greater
                                                    risk for serious GI
                                                    events. These events may occur at any time during therapy and
                                                    without warning.
                                                </li>
                                                <li>
                                                    NSAID use may increase the risk of hyperkalemia, particularly in the
                                                    elderly, diabetics,
                                                    renal disease, and with concomitant use of other agents capable of
                                                    inducing hyperkalemia
                                                    (eg, ACE inhibitors). Monitor potassium closely.
                                                </li>
                                                <li>
                                                    NSAID use may compromise existing renal function; dose-dependent
                                                    decreases in prostaglandin
                                                    synthesis may result from NSAID use, reducing renal blood flow which
                                                    may cause renal
                                                    decompensation (usually reversible). Patients with impaired renal
                                                    function, dehydration,
                                                    hypovolemia, heart failure, hepatic impairment, those taking
                                                    diuretics and ACE inhibitors,
                                                    and elderly patients are at greater risk of renal toxicity.
                                                    Rehydrate patient before
                                                    starting therapy; monitor renal function closely. Long-term NSAID
                                                    use may result in renal
                                                    papillary necrosis and other renal injury.
                                                </li>
                                            </ol>
                                        </div>
                                    </div>
                                </div>
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#diclofenacCollapseThree"
                                        aria-expanded="false" aria-controls="diclofenacCollapseThree">
                                        <div class="card-header" id="diclofenacheadingThree">
                                            <h1 class="card-heading">Interactions</h1>
                                        </div>
                                    </a>
                                    <div id="diclofenacCollapseThree" class="collapse"
                                        aria-labelledby="diclofenacheadingThree" data-parent="#diclofenac">
                                        <div class="card-body">
                                            <ul>
                                                <li>
                                                    <b>Diclofenac+ Aspirin:</b> The combined use of low-dose or
                                                    high-dose aspirin with other
                                                    nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the
                                                    potential for serious
                                                    gastrointestinal (GI) toxicity.
                                                </li>
                                                <li>Concomitant administration of NSAIDs is considered contraindicated
                                                    or not recommended.
                                                </li>
                                                <li>patients should be advised to take the medications with food and to
                                                    immediately report
                                                    signs and symptoms of GI ulceration.</li>
                                                <li>Diclofenac + pentoxifylline : The use of pentoxifylline has been
                                                    associated with bleeding
                                                    and/or prolongation in prothrombin time. </li>
                                                <li>Monitoring of INR</li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="tab-pane fade" id="pills-ketorolac" role="tabpanel"
                            aria-labelledby="pills-ketorolac-tab">


                            <div id="ketorolac">
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#ketorolacCollapseOne"
                                        role="button" aria-expanded="false" aria-controls="ketorolacCollapseOne">
                                        <div class="card-header" id="ketorolacheadingOne">
                                            <h1 class="card-heading">Dose</h1>
                                        </div>
                                    </a>
                                    <div id="ketorolacCollapseOne" class="collapse"
                                        aria-labelledby="ketorolacheadingOne" data-parent="#ketorolac">
                                        <div class="card-body">
                                            <h3>Pain management (acute; moderately severe) in patients ≥50 kg: Note:
                                            </h3>
                                            <p class="card-p">
                                                combined duration of treatment (for parenteral and oral) is 5 days; do
                                                not increase dose or
                                                frequency; supplement with low-dose opioids if needed for breakthrough
                                                pain. Oral formulation
                                                should not be given as an initial dose.
                                                <ul>
                                                    <li>combined duration of treatment (for parenteral and oral) is 5
                                                        days; do not increase dose
                                                        or frequency; supplement with low-dose opioids if needed for
                                                        breakthrough pain. Oral
                                                        formulation should not be given as an initial dose.</li>
                                                    <li>Weight less than 50 kg: 15 mg IM/IV every 6 hours or as a single
                                                        dose; maximum dose: 60
                                                        mg/day</li>
                                                </ul>
                                            </p>
                                            <h3>Oral Continuation therapy (should not be given as an initial dose):</h3>
                                            <p class="card-p">
                                                Weight 50 kg or more: 20 mg orally once followed by 10 mg every 4 to 6
                                                hours as needed
                                            </p>
                                            <p class="card-p">
                                                Weight less than 50 kg: 10 mg orally once followed by 10 mg every 4 to 6
                                                hours as needed
                                            </p>
                                            <p>
                                                <b>Max:</b> Total systemic therapy should not exceed 5 days. <br>
                                                -Weight 50 kg or more: 120 mg/day <br>
                                                -Weight less than 50 kg: 60 mg/day <br>
                                                - Maximum oral dose: 40 mg/day <br><br>
                                                <b>Hepatic:</b>Use with caution; if signs/symptoms of liver dysfunction
                                                develop or an abnormal
                                                liver
                                                test is obtained, evaluate for hepatotoxicity <br>
                                                -Discontinue therapy for clinical signs/symptoms of liver disease or the
                                                presence of a
                                                systemic manifestation (eosinophilia, rash, etc.) <br>
                                                <b>Renal:</b> IV: 15 mg as a single dose or 15 mg every 6 hours
                                                (maximum: 60 mg/day) <br>
                                                Oral: 10 mg, followed by 10 mg every 4 to 6 hours as needed; maximum: 40
                                                mg/day; oral dosing
                                                is intended to be a continuation of IM or IV therapy only <br>
                                                Advanced impairment or patients at risk for renal failure due to volume
                                                depletion: Use is
                                                contraindicated <br>
                                                Other recommendations: <br>
                                                GFR &gt;50 mL/minute/1.73 m2: 15 to 30 mg IM or IV every 6 hours <br>
                                                GFR 10 to 50 mL/minute/1.73 m2: Preferably avoid or administer 7.5 to 15
                                                mg IM or IV every 6
                                                hours <br>
                                                GFR &lt;10 mL/minute/1.73 m2: Preferably avoid <br>
                                                Hemodialysis: Preferably avoid <br>

                                            </p>
                                        </div>
                                    </div>
                                </div>
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#ketorolacCollapseTwo"
                                        role="button" aria-expanded="false" aria-controls="ketorolacCollapseTwo">
                                        <div class="card-header" id="ketorolacheadingTwo">
                                            <h1 class="card-heading">Warnings</h1>
                                        </div>
                                    </a>
                                    <div id="ketorolacCollapseTwo" class="collapse"
                                        aria-labelledby="ketorolacheadingTwo" data-parent="#ketorolac">
                                        <div class="card-body">
                                            <ol>
                                                <li>
                                                    [US Boxed Warning]: Inhibits platelet function; contraindicated in
                                                    patients with
                                                    cerebrovascular bleeding (suspected or confirmed), hemorrhagic
                                                    diathesis, incomplete
                                                    hemostasis and patients at high risk for bleeding Long-term oral
                                                    acetaminophen
                                                    administration at a dosage of 4 g/day has been shown to increase
                                                    international normalized
                                                    ratio in some patients stabilized on warfarin.
                                                </li>
                                                <li>[US Boxed Warning]: NSAIDs cause an increased risk of serious (and
                                                    potentially fatal)
                                                    adverse cardiovascular thrombotic events, including MI and stroke.
                                                    Risk may occur early
                                                    during treatment and may increase with duration of use.</li>
                                                <li>[US Boxed Warning]: NSAIDs cause increased risk of serious GI
                                                    inflammation, ulceration,
                                                    bleeding, and perforation (may be fatal); elderly patients and
                                                    patients with history of
                                                    peptic ulcer disease and/or GI bleeding are at greater risk of
                                                    serious GI events. These
                                                    events may occur at any time during therapy and without warning.
                                                </li>
                                                <li>[US Boxed Warning]: Ketorolac is contraindicated in patients with
                                                    advanced renal
                                                    impairment and in patients at risk for renal failure due to volume
                                                    depletion.</li>
                                                <li>[US Boxed Warning]: Concurrent use of ketorolac with aspirin or
                                                    other NSAIDs is
                                                    contraindicated due to the increased risk of adverse reactions.</li>
                                                <li>[US Boxed Warning]: Oral therapy is only indicated for use as
                                                    continuation treatment,
                                                    following parenteral ketorolac and is not indicated for minor or
                                                    chronic painful conditions.
                                                </li>
                                                <li>[US Boxed Warning]: Systemic ketorolac is indicated for short term
                                                    (≤5 days) use in adults
                                                    for treatment of moderately severe acute pain requiring opioid-level
                                                    analgesia. The combined
                                                    therapy duration (oral and parenteral) should not exceed 5 days due
                                                    to the increased risk of
                                                    serious adverse events.</li>
                                            </ol>
                                        </div>
                                    </div>
                                </div>
                            </div>

                        </div>
                        <div class="tab-pane fade" id="pills-meloxicam" role="tabpanel"
                            aria-labelledby="pills-meloxicam-tab">
                            <div id="meloxicam">
                                <div class="card">

                                    <a class="collapsed" data-toggle="collapse" href="#meloxicamCollapseOne"
                                        role="button" aria-expanded="false" aria-controls="meloxicamCollapseOne">
                                        <div class="card-header" id="meloxicamheadingOne">
                                            <h1 class="card-heading">
                                                Dose
                                            </h1>
                                        </div>
                                    </a>
                                    <div id="meloxicamCollapseOne" class="collapse"
                                        aria-labelledby="meloxicamheadingOne" data-parent="#meloxicam">
                                        <div class="card-body">
                                            <p class="card-p">
                                                7.5 mg/day
                                            </p>
                                            <ul>
                                                <li>
                                                    <b>Max:</b> 15 mg/day PO for tablets and oral suspension; 10 mg/day
                                                    PO for capsules.
                                                </li>
                                                <li><b>Hepatic:</b> No dose adjustment is needed in mild to moderate
                                                    hepatic impairment.
                                                    Meloxicam is not recommended in patients with severe hepatic
                                                    insufficiency; sufficient data
                                                    are lacking.</li>
                                                <li><b>Renal:</b> CrCl more than 20 mL/minute: No dosage adjustment
                                                    needed.
                                                    CrCl 20 mL/minute or less: Meloxicam is not recommended in patients
                                                    with severe renal
                                                    impairment; sufficient data are lacking.
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#meloxicamCollapseTwo"
                                        role="button" aria-expanded="false" aria-controls="meloxicamCollapseTwo">
                                        <div class="card-header" id="meloxicamheadingTwo">
                                            <h1 class="card-heading">Warnings</h1>
                                        </div>
                                    </a>
                                    <div id="meloxicamCollapseTwo" class="collapse"
                                        aria-labelledby="meloxicamheadingTwo" data-parent="#meloxicam">
                                        <div class="card-body">
                                            <ol>
                                                <li>Acute myocardial infarction, angina, cardiac arrhythmias, cardiac
                                                    disease,
                                                    cerebrovascular disease, coronary artery disease, heart failure,
                                                    hypertension, myocardial
                                                    infarction, peripheral vascular disease, stroke, tachycardia,
                                                    thromboembolism
                                                    Meloxicam, like all NSAIDs, may exacerbate hypertension and
                                                    congestive heart failure and may
                                                    cause an increased risk of serious cardiovascular thromboembolism,
                                                    acute myocardial
                                                    infarction, and stroke.
                                                </li>
                                                <li>Alcoholism, anticoagulant therapy, corticosteroid therapy, GI
                                                    bleeding, GI disease, GI
                                                    perforation, peptic ulcer disease, tobacco smoking, all increase
                                                    risk of ulceration and GI
                                                    bleeding. <br>
                                                    (To minimize the potential risk for an adverse GI event, the lowest
                                                    effective dose of
                                                    meloxicam should be used for the shortest possible duration. Serious
                                                    GI tract effects such
                                                    as GI bleeding, inflammation, stomach or other GI perforation, and
                                                    ulceration, can occur
                                                    without warning or symptoms in patients receiving NSAIDs. )
                                                </li>
                                                <li>
                                                    The recommended maximum daily dose should not be exceeded in case of
                                                    insufficient
                                                    therapeutic effect, nor should an additional NSAID be added to the
                                                    therapy because this may
                                                    increase the toxicity while therapeutic advantage has not been
                                                    proven. The use of Meloxicam
                                                    Orodispersible Tablets with concomitant NSAIDs including
                                                    cyclooxygenase-2 selective
                                                    inhibitors should be avoided.
                                                </li>
                                                <li>
                                                    As with most NSAIDs, occasional increases in serum transaminase
                                                    levels, increases in serum
                                                    bilirubin or other liver function parameters, as well as increases
                                                    in serum creatinine and
                                                    blood urea nitrogen as well as other laboratory disturbances, have
                                                    been reported. The
                                                    majority of these instances involved transitory and slight
                                                    abnormalities. Should any such
                                                    abnormality prove significant or persistent, the administration of
                                                    Meloxicam should be
                                                    stopped and appropriate investigations undertaken.
                                                </li>
                                                <li>
                                                    Sodium, potassium and water retention
                                                    Induction of sodium, potassium and water retention and interference
                                                    with the natriuretic
                                                    effects of diuretics may occur with NSAIDs. Furthermore, a decrease
                                                    of the antyhypertensive
                                                    effect of antyhypertensive drugs can occur. Consequently, oedema,
                                                    cardiac failure or
                                                    hypertension may be precipitated or exacerbated in susceptible
                                                    patients as a result.
                                                </li>
                                                <li>
                                                    Hyperkalaemia
                                                </li>
                                                <li>
                                                    Hyperkalaemia can be favoured by diabetes or concomitant treatment
                                                    known to increase
                                                    kalaemia. Regular monitoring of potassium values should be performed
                                                    in
                                                    such cases.
                                                </li>
                                            </ol>
                                        </div>
                                    </div>
                                </div>
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#meloxicamCollapseThree"
                                        aria-expanded="false" aria-controls="meloxicamCollapseThree">
                                        <div class="card-header" id="meloxicamheadingThree">
                                            <h1 class="card-heading">Contraindications</h1>
                                        </div>
                                    </a>
                                    <div id="meloxicamCollapseThree" class="collapse"
                                        aria-labelledby="meloxicamheadingThree" data-parent="#meloxicam">
                                        <div class="card-body">
                                            <p class="card-p">
                                                Meloxicam is contraindicated in treatment of perioperative pain after
                                                coronary artery bypass
                                                surgery (CABG).
                                            </p>
                                        </div>
                                    </div>
                                </div>
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#meloxicamCollapseFour"
                                        role="button" aria-expanded="false" aria-controls="meloxicamCollapseFour">
                                        <div class="card-header" id="meloxicamheadingFour">
                                            <h1 class="card-heading">Monitoring</h1>
                                        </div>
                                    </a>
                                    <div id="meloxicamCollapseFour" class="collapse"
                                        aria-labelledby="meloxicamheadingFour" data-parent="#meloxicam">
                                        <div class="card-body">
                                            <p class="card-p">
                                                Careful monitoring of diuresis and renal function is recommended in
                                                patients with the
                                                following risk factors: (HYPERKALEMIA)
                                            </p>
                                            <ul>
                                                <li>Elderly</li>
                                                <li>Concomitant treatments such as ACE inhibitors, angiotensin-II
                                                    antagonists, sartans,
                                                    diuretics </li>
                                                <li>Hypovolemia (whatever the cause)</li>
                                                <li>Congestive heart failure</li>
                                                <li>Renal failure</li>
                                                <li>Nephrotic syndrome</li>
                                                <li>Lupus nephropathy</li>
                                                <li>Severe hepatic dysfunction (serum albumin &lt;25 g/l or Child-Pugh
                                                    score 10)'</li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="tab-pane fade" id="opioids" role="tabpanel" aria-labelledby="opioids-tab">
                <div class="mainContent">
                    <ul class="nav nav-pills mb-3" id="pills-tab-opioids" role="tablist">
                        <li class="nav-item">
                            <a class="nav-link active" id="pills-fentanyl-tab" data-toggle="pill" href="#pills-fentanyl"
                                role="tab" aria-controls="pills-fentanyl" aria-selected="true">Fentanyl</a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" id="pills-morphine-sulfate-tab" data-toggle="pill"
                                href="#pills-morphine-sulfate" role="tab" aria-controls="pills-morphine-sulfate"
                                aria-selected="false">Morphine sulfate</a>
                        </li>
                    </ul>
                    <div class="tab-content" id="pills-tab-opioidsContent">
                        <div class="tab-pane fade show active" id="pills-fentanyl" role="tabpanel"
                            aria-labelledby="pills-fentanyl-tab">
                            <div class="instruction">
                                <h2 class="fs-title">N.B</h2>
                                <p>use in hospitals only due to risk of respiratory depression</p>
                            </div>
                            <div id="fentanyl">
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#fentanylcollapseOne"
                                        role="button" aria-expanded="false" aria-controls="fentanylcollapseOne">
                                        <div class="card-header" id="fentanylheadingOne">
                                            <h1 class="card-heading">Dose</h1>
                                        </div>
                                    </a>

                                    <div id="fentanylcollapseOne" class="collapse" aria-labelledby="fentanylheadingOne"
                                        data-parent="#fentanyl">
                                        <div class="card-body">
                                            <ul>
                                                <li>
                                                    Loading dose: 1-2 mcg/ kg. ( 25- 100 mcg)
                                                </li>
                                                <li>Loading dose: 1-2 mcg/ kg. ( 25- 100 mcg)
                                                    <br>
                                                    AND/OR 0.7-10 mcg/Kg/hr infusion ( 50-700 mcg/ hr)
                                                </li>
                                                <li>For Most pts. Around( 50- 200 mcg/hr) infusion with as needed
                                                    intermittent infusion.</li>
                                            </ul>
                                            <h4>Adjustment</h4>
                                            <ul>
                                                <li><b>Renal impairment, GFR 10 to 50 mL/min:</b> Administer 75% of the
                                                    normal fentanyl dose.
                                                </li>
                                                <li><b>Renal impairment, GFR less than 10 mL/min:</b> Administer 50% of
                                                    the normal fentanyl
                                                    dose.</li>
                                                <li><b>(Transdermal patch) Renal impairment (mild to moderate):</b>
                                                    Initiate with 50% of the
                                                    usual dosage.</li>
                                                <li><b>(Transdermal patch) Renal impairment (severe):</b> Avoid use.
                                                </li>
                                                <li><b>(Transdermal patch) Hepatic impairment (mild to moderate):</b>
                                                    Initiate with 50% of the
                                                    usual dosage.</li>
                                                <li><b>(Transdermal patch) Hepatic impairment (severe):</b> Avoid use.
                                                </li>
                                                <li><b>(Transdermal patch) Geriatric:</b> Initiate at the lower end of
                                                    the dosing range and
                                                    titrate slowly.</li>
                                            </ul>
                                            <p class="card-p">
                                                <b>Onset:</b> &lt; 1-2 mins
                                            </p>
                                            <p class="card-p">
                                                <b>Duration of intermittent dose:</b> &lt; 30-60 mins
                                            </p>
                                        </div>
                                    </div>
                                </div>

                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#fentanylcollapseTwo"
                                        role="button" aria-expanded="false" aria-controls="fentanylcollapseTwo">
                                        <div class="card-header" id="fentanylheadingTwo">
                                            <h1 class="card-heading">Contraindications</h1>
                                        </div>
                                    </a>
                                    <div id="fentanylcollapseTwo" class="collapse" aria-labelledby="fentanylheadingTwo"
                                        data-parent="#fentanyl">
                                        <div class="card-body">
                                            <ul>
                                                <li>
                                                    Acute or postoperative pain including use after outpatient or day
                                                    surgeries, or if analgesia
                                                    is required for a short time period; risk of life-threatening
                                                    hypoventilation.
                                                </li>
                                                <li>Acute or severe bronchial asthma.</li>
                                                <li>Known or suspected gastrointestinal obstruction.</li>
                                                <li>Hypersensitivity to fentanyl or any components of the product.</li>
                                                <li>Mild or intermittent pain management; risk of life-threatening
                                                    hypoventilation.</li>
                                                <li>Opioid non-tolerant patients.</li>
                                                <li>Known or suspected paralytic ileus.</li>
                                                <li>Significant respiratory depression, especially in unmonitored
                                                    settings or settings that
                                                    lack resuscitative equipment.</li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>

                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#fentanylcollapseThree"
                                        role="button" aria-expanded="false" aria-controls="fentanylcollapseThree">
                                        <div class="card-header" id="fentanylheadingThree">
                                            <h1 class="card-heading">Adverse drug effects</h1>
                                        </div>
                                    </a>
                                    <div id="fentanylcollapseThree" class="collapse"
                                        aria-labelledby="fentanylheadingThree" data-parent="#fentanyl">
                                        <div class="card-body">
                                            <ul>
                                                <li><b>Cardiovascular:</b> Bradyarrhythmia, Chest pain (1% or greater),
                                                    Hypotension (2%) </li>
                                                <li><b>Endocrine metabolic:</b> Adrenal insufficiency </li>
                                                <li><b>Gastrointestinal:</b> Paralytic ileus </li>
                                                <li><b>Neurologic:</b> Coma, Seizure </li>
                                                <li><b>Respiratory:</b> Respiratory depression (1%) </li>
                                                <li><b>Other:</b> Drug dependence, Neonatal Abstinence Syndrome,
                                                    Serotonin syndrome </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>

                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#fentanylcollapseFour"
                                        role="button" aria-expanded="false" aria-controls="fentanylcollapseFour">
                                        <div class="card-header" id="fentanylheadingFour">
                                            <h1 class="card-heading">Interactions</h1>
                                        </div>
                                    </a>
                                    <div id="fentanylcollapseFour" class="collapse"
                                        aria-labelledby="fentanylheadingFour" data-parent="#fentanyl">
                                        <div class="card-body">
                                            <ul>
                                                <li> CYP 3A4 inhibitors and inducers </li>
                                                <li> CNS depressants ( Benzodiazepines...) </li>
                                                <li> Addiction, withdrawal symptoms (Never stop suddenly) </li>
                                                <li> lipophilic drug ..so may accumulate in Adipose tissues with
                                                    repeated or prolonged </li>
                                                administration ) </li>
                                                <li> Chest wall rigidity may Occur with </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>

                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#fentanylcollapseFive"
                                        role="button" aria-expanded="false" aria-controls="fentanylcollapseFive">
                                        <div class="card-header" id="fentanylheadingFive">
                                            <h1 class="card-heading">Toxicity treatment</h1>
                                        </div>
                                    </a>
                                    <div id="fentanylcollapseFive" class="collapse"
                                        aria-labelledby="fentanylheadingFive" data-parent="#fentanyl">
                                        <div class="card-body">
                                            <ul>
                                                <li> Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Patients may only
                                                    need observation.
                                                    MANAGEMENT OF SEVERE TOXICITY: Administer oxygen and assist
                                                    ventilation for respiratory
                                                    depression. Naloxone is the antidote indicated for severe toxicity
                                                    (respiratory or CNS
                                                    depression). Orotracheal intubation for airway protection should be
                                                    performed early in cases
                                                    of obtundation and/or respiratory depression that do not respond to
                                                    naloxone, or in patients
                                                    who develop severe acute lung injury.</li>
                                                <li> Antidote: NALOXONE, an opioid antagonist, is the specific antidote.
                                                    Naloxone can be given
                                                    intravascularly, intramuscularly, subcutaneously, intranasally or
                                                    endotracheally. The usual
                                                    dose is 0.4 to 2.0 mg IV. In patients with suspected opioid
                                                    dependence, incremental doses of
                                                    0.2 mg IV should be administered, titrated to reversal of
                                                    respiratory depression and coma,
                                                    to
                                                    avoid precipitating acute opioid withdrawal. Doses may be repeated
                                                    every 2 to 3 minutes up
                                                    to
                                                    20 mg. Very high doses are rarely needed</li>
                                                <li> . Seizure: Seizures are rare, but may be a result of hypoxia.
                                                    Treatment includes ensuring
                                                    adequate oxygenation, and administering intravenous benzodiazepines;
                                                    propofol or
                                                    barbiturates
                                                    may be indicated, if seizures persist. Patients with seizures and
                                                    myoclonus after massive
                                                    intrathecal morphine overdose have required barbiturate coma with
                                                    continuous EEG monitoring.
                                                </li>
                                                <li> Acute lung injury: Acute lung injury can develop in a small
                                                    proportion of patients after
                                                    an
                                                    acute opioid overdose. The pathophysiology is unclear. Patients
                                                    should be observed for 4 to
                                                    6
                                                    hours after overdose to evaluate for hypoxia and/or the development
                                                    of acute lung injury.
                                                    Continuous oxygen therapy, pulse oximetry, PEEP and mechanical
                                                    ventilation may be necessary.
                                                </li>
                                                <li> Hypotensive episode: Hypotension is often reversed by naloxone.
                                                    Initially treat with a
                                                    saline bolus, if patient can tolerate a fluid load; then add
                                                    adrenergic vasopressors to
                                                    raise
                                                    mean arterial pressure if hypotension persists.</li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>

                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#fentanylcollapseSix"
                                        role="button" aria-expanded="false" aria-controls="fentanylcollapseSix">
                                        <div class="card-header" id="fentanylheadingSix">
                                            <h1 class="card-heading">Cases to prescribe Fentanyl</h1>
                                        </div>
                                    </a>
                                    <div id="fentanylcollapseSix" class="collapse" aria-labelledby="fentanylheadingSix"
                                        data-parent="#fentanyl">
                                        <div class="card-body">
                                            <ul>
                                                <li>If patient is on mechanical ventilator …. Use Fentanyl, Morphine.
                                                </li>
                                                <li>If patient Extubated with Moderate to severe non-neuropathic pain
                                                    ... Use IV fentanyl,
                                                    Morphine</li>
                                                <li>If patient is with Renal or Hepatic insufficiency ...... Use IV
                                                    Fentanyl</li>
                                                <li>If patient Is hemodynamically Non- stable ... Use fentanyl</li>
                                                <li>If patient has bronchospasm ... use fentanyl</li>
                                                <li>If patient requires neurologic assessment ...Use Remifentanil</li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>

                            </div>
                        </div>
                        <div class="tab-pane fade" id="pills-morphine-sulfate" role="tabpanel"
                            aria-labelledby="pills-morphine-sulfate-tab">

                            <div id="morphine-sulfate">
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#morphine-sulfatecollapseOne"
                                        role="button" aria-expanded="false" aria-controls="morphine-sulfatecollapseOne">
                                        <div class="card-header" id="morphine-sulfateheadingOne">
                                            <h1 class="card-heading">Dose</h1>
                                        </div>
                                    </a>

                                    <div id="morphine-sulfatecollapseOne" class="collapse"
                                        aria-labelledby="morphine-sulfateheadingOne" data-parent="#morphine-sulfate">
                                        <div class="card-body">
                                            <p class="card-p">
                                                -LD : 2-10 mg
                                                -Maintainance: 2-4 mg every 1-2 hr ( intermittent) or 2-30 mg/ hr (
                                                infusion)
                                            </p>
                                            <h4>Adjustment</h4>
                                            <ul>
                                                <li>Renal impairment: Initiate therapy with lower doses and titrate
                                                    slowly in patients with
                                                    renal failure; use care with epidural administration in patients
                                                    with renal dysfunction as
                                                    half-life may be prolonged. Monitoring is necessary due to altered
                                                    pharmacokinetics in
                                                    patients with renal failure.</li>
                                                <li>Renal impairment (Mild to moderate, GFR 10 to 50 mL/min or serum
                                                    creatinine 1.7 to 7.9
                                                    mg/dL
                                                    (150 to 698 mcmol/L) in pediatric patients: Reduce dose by 25%</li>
                                                <li>Renal impairment (Severe, GFR less than 10 mL/min or serum
                                                    creatinine greater than 7.9
                                                    mg/dL
                                                    (698 mcmol/L)) in pediatric patients: Reduce dose by 50% or consider
                                                    alternative opioid
                                                    analgesics</li>
                                                <li>Hepatic impairment: Initiate therapy with lower doses and titrate
                                                    slowly in patients with
                                                    cirrhosis; use care with epidural administration in patients with
                                                    hepatic dysfunction as
                                                    half-life may be prolonged. Monitoring is necessary due to altered
                                                    pharmacokinetics in
                                                    patients with cirrhosis.</li>
                                                <li>Hepatic impairment in pediatric patients: Avoid use or reduce dose
                                                </li>
                                                <li>Geriatric: Start at low end of dosing range and titrate slowly; take
                                                    care in dose
                                                    selection
                                                    due to increased likelihood of renal dysfunction.</li>
                                                <li>Concomitant use with benzodiazepines or other CNS depressants: If
                                                    concomitant use is
                                                    necessary, limit dosages and durations to the minimum required.</li>
                                                <li>(Morphabond(TM) ER) Concomitant use of CNS depressants: Initiate
                                                    with lowest possible dose
                                                    of 15 mg every 12 hours; consider lower dosage of the concomitant
                                                    CNS depressant</li>

                                            </ul>
                                            <p class="card-p">
                                                <b>Onset :</b> 5-10 min
                                            </p>
                                            <p class="card-p">
                                                <b>Duration of intermittent infusion:</b> 4-5 hrs.
                                            </p>
                                        </div>
                                    </div>
                                </div>
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#morphine-sulfatecollapseTwo"
                                        role="button" aria-expanded="false" aria-controls="morphine-sulfatecollapseTwo">
                                        <div class="card-header" id="morphine-sulfateheadingTwo">
                                            <h1 class="card-heading">Contraindications</h1>
                                        </div>
                                    </a>
                                    <div id="morphine-sulfatecollapseTwo" class="collapse"
                                        aria-labelledby="morphine-sulfateheadingTwo" data-parent="#morphine-sulfate">
                                        <div class="card-body">
                                            <ul>
                                                <li> Acute alcoholism and delirium tremens are contraindications to use
                                                    of morphine rectal
                                                    suppositories
                                                </li>
                                                <li> Acute or severe bronchial asthma in an unmonitored setting or in
                                                    the absence of
                                                    resuscitative equipment
                                                </li>
                                                <li> Biliary tract surgery, post-procedure, is a contraindication to use
                                                    of morphine rectal
                                                    suppositories
                                                </li>
                                                <li> Brain tumor is contraindicated with use of morphine rectal
                                                    suppositories.
                                                </li>
                                                <li> Cardiac arrhythmias are a contraindication to use of morphine
                                                    rectal suppositories
                                                </li>
                                                <li> CNS depression, severe, is a contraindication to use of morphine
                                                    rectal suppositories
                                                </li>
                                                <li> Convulsive disorders are a contraindication to use of morphine
                                                    rectal suppositories
                                                </li>
                                                <li> Concomitant use with MAOIs, or use of MAOIs within 14 days
                                                </li>
                                                <li> Known or suspected gastrointestinal obstruction
                                                </li>
                                                <li> Head injuries are a contraindication to use of morphine rectal
                                                    suppositories
                                                </li>
                                                <li> Heart failure, secondary to chronic lung disease, is a
                                                    contraindication to use of
                                                    morphine
                                                    rectal suppositories
                                                </li>
                                                <li> Hypercarbia
                                                </li>
                                                <li> Hypersensitivity to morphine, morphine salts, or any component of
                                                    the product
                                                </li>
                                                <li> Increased intracranial or cerebrospinal pressure is a
                                                    contraindication to use of morphine
                                                    rectal suppositories
                                                </li>
                                                <li> Neuraxial analgesia contraindications
                                                </li>
                                                <li> Known or suspected paralytic ileus
                                                </li>
                                                <li> Respiratory depression; in the absence of resuscitative equipment
                                                    or in unmonitored
                                                    settings
                                                </li>
                                                <li> Surgical abdomen, suspected, is a contraindication to use of
                                                    morphine rectal
                                                    suppositories
                                                </li>
                                                <li> Surgical anastomosis is a contraindication to use of morphine
                                                    rectal suppositories
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>

                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#morphine-sulfatecollapseThree"
                                        role="button" aria-expanded="false"
                                        aria-controls="morphine-sulfatecollapseThree">
                                        <div class="card-header" id="morphine-sulfateheadingThree">
                                            <h1 class="card-heading">Precautions</h1>
                                        </div>
                                    </a>
                                    <div id="morphine-sulfatecollapseThree" class="collapse"
                                        aria-labelledby="morphine-sulfateheadingThree" data-parent="#morphine-sulfate">
                                        <div class="card-body">
                                            <ul>
                                                <li> avoid concomitant use of any benzodiazepine due to increased risk
                                                    of overdose. Avoid
                                                    concomitant use of gabapentin or pregabalin due to increased risk of
                                                    severe sedation-related
                                                    adverse events including respiratory depression and death (unless
                                                    when transitioning away
                                                    from
                                                    opioid therapy or with goal of reduced opioid use, although such
                                                    uses require caution).
                                                </li>
                                                <li> Abuse: Abuse of controlled-release capsules or tablets by
                                                    parenteral route may result in
                                                    local tissue necrosis, infection, pulmonary granulomas, and
                                                    increased risk of endocarditis
                                                    and
                                                    valvular heart injury due to the presence of talc.
                                                </li>
                                                <li> Cardiovascular: Preexisting circulatory shock may reduce cardiac
                                                    output and blood
                                                    pressure;
                                                    avoid use.
                                                </li>
                                                <li> Cardiovascular: Severe hypotension, including orthostatic
                                                    hypotension and syncope, in
                                                    ambulatory patients may occur; especially in patients with
                                                    compromised ability to maintain
                                                    blood pressure; monitoring recommended; consider alternative
                                                    non-opioid analgesic if
                                                    possible.
                                                </li>
                                                <li> Cardiovascular: Ventricular response rate may be increased in
                                                    patients with
                                                    supraventricular
                                                    tachycardias, including atrial flutter.
                                                </li>
                                                <li> Concomitant use: Avoid concomitant use with mixed
                                                    agonist/antagonist (eg, pentazocine,
                                                    nalbuphine, butorphanol) or partial agonists (eg, buprenorphine).
                                                </li>
                                                <li> Concomitant use: Avoid concomitant use of MAOIs or within 14 days
                                                    of discontinuation.
                                                </li>
                                                <li> Endocrine and metabolic: Adrenocortical insufficiency (eg, Addison
                                                    disease); increased
                                                    risk
                                                    for toxicity; dosage reduction recommended
                                                </li>
                                                <li> Endocrine and metabolic: Opioids may rarely lead to adrenal
                                                    insufficiency due to
                                                    inadequate
                                                    amounts of cortisol. If adrenal insufficiency is suspected, perform
                                                    diagnostic testing,
                                                    treat
                                                    with corticosteroids if confirmed, wean patient off of opioid if
                                                    appropriate, and continue
                                                    to
                                                    assess adrenal function.
                                                </li>
                                                <li> Endocrine and metabolic: Hypothyroidism or myxedema; increased risk
                                                    for toxicity; dosage
                                                    reduction recommended
                                                </li>
                                                <li> Gastrointestinal: Difficulty with swallowing may occur due to
                                                    tablet stickiness and
                                                    swelling, including choking, gagging, regurgitation, and having a
                                                    tablet stuck in the
                                                    throat.
                                                    Do not presoak, lick, or wet tablets prior to use. Take tablets
                                                    singly and immediately after
                                                    placing in the mouth with enough water to ensure complete
                                                    swallowing; alternative therapy
                                                    may
                                                    be required.
                                                </li>
                                                <li> Gastrointestinal: Intestinal obstruction or exacerbation of
                                                    diverticulitis may occur due
                                                    to
                                                    tablet stickiness and swelling, especially in patients with a small
                                                    gastrointestinal lumen
                                                    (eg
                                                    esophageal or colon cancer); alternative therapy may be required.
                                                </li>
                                                <li> Gastrointestinal: Acute abdominal conditions; diagnosis or clinical
                                                    course may be
                                                    obscured
                                                </li>
                                                <li> Hepatic: Spasm of the sphincter of Oddi and increased serum amylase
                                                    levels may occur in
                                                    patients with biliary tract disease; monitoring recommended.
                                                </li>
                                                <li> Hepatic: Severe hepatic impairment; increased risk of toxicity;
                                                    dosage reduction
                                                    recommended
                                                </li>
                                                <li> Immunologic: Anaphylaxis has been reported.
                                                </li>
                                                <li> Neurologic: Impaired consciousness or coma; avoid use
                                                </li>
                                                <li> Neurologic: Potentially life-threatening serotonin syndrome may
                                                    occur, particularly with
                                                    concomitant use of serotonergic drugs.
                                                </li>
                                                <li> Neurologic: Cordotomy or other interruption of pain transmission
                                                    pathways; discontinue
                                                    use
                                                    prior to procedure
                                                </li>
                                                <li> Neurologic: Those with brain tumors or increased intracranial
                                                    pressure may have
                                                    exaggerated
                                                    respiratory depressant effects and further elevation of
                                                    cerebrospinal fluid pressure; the
                                                    clinical course of head injury may be obscured; monitoring
                                                    recommended.
                                                </li>
                                                <li> Neurologic: Myoclonic-like spasm of lower extremities has been
                                                    reported with intrathecal
                                                    doses of more than 20 mg/day.
                                                </li>
                                                <li> Neurologic: Seizure disorders may be induced or aggravated;
                                                    monitoring recommended.
                                                </li>
                                                <li> Neurologic: Inflammatory masses, such as granulomas, due to
                                                    indwelling intrathecal
                                                    catheters
                                                    may result in neurologic impairment, including paralysis.
                                                </li>
                                                <li> Prolonged use: Long-term use of opioids may be associated with
                                                    decreased sex hormone
                                                    levels
                                                    and symptoms such as reduced interest in sex, impotence, or
                                                    infertility. Laboratory
                                                    evaluation
                                                    may be warranted.
                                                </li>
                                                <li> Psychiatric: Toxic psychosis; increased risk for toxicity
                                                </li>
                                                <li> Renal: Severe renal impairment; increased risk for toxicity; dosage
                                                    reduction recommended
                                                </li>
                                                <li> Reproductive: Prostatic hypertrophy or urethral stricture;
                                                    increased risk for toxicity;
                                                    dosage reduction recommended
                                                </li>
                                                <li> Respiratory: Increased risk for further respiratory depression in
                                                    patients with
                                                    significant
                                                    chronic obstructive pulmonary disease or cor pulmonale, especially
                                                    during treatment
                                                    initiation
                                                    and titration; monitoring recommended, particularly during treatment
                                                    initiation and
                                                    titration
                                                    or when using concomitant CNS depressants
                                                </li>
                                                <li> Special populations: Fatal respiratory depression may occur in
                                                    opioid-intolerant
                                                    patients.
                                                </li>
                                                <li> Special populations: Elderly or debilitated patients are at
                                                    increased risk for
                                                    respiratory
                                                    depression; monitor closely, particularly during treatment
                                                    initiation and titration or when
                                                    using concomitant CNS depressants and reduce dosage if necessary.
                                                </li>
                                                <li> Withdrawal: Abrupt withdrawal may result in severe withdrawal
                                                    symptoms and should be
                                                    avoided. Serious withdrawal symptoms, including uncontrolled pain,
                                                    psychological distress,
                                                    and
                                                    suicide, may occur upon sudden dose decrease or discontinuation in
                                                    patients who are
                                                    physically
                                                    dependent on opioid medications; do not discontinue abruptly and
                                                    create a patient-specific
                                                    plan to taper the opioid gradually.
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>

                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#morphine-sulfatecollapseFour"
                                        role="button" aria-expanded="false"
                                        aria-controls="morphine-sulfatecollapseFour">
                                        <div class="card-header" id="morphine-sulfateheadingFour">
                                            <h1 class="card-heading">Side effects</h1>
                                        </div>
                                    </a>
                                    <div id="morphine-sulfatecollapseFour" class="collapse"
                                        aria-labelledby="morphine-sulfateheadingFour" data-parent="#morphine-sulfate">
                                        <div class="card-body">
                                            <ul>
                                                <li><b>Cardiovascular:</b> Cardiac arrest, Disorder of cardiovascular
                                                    system, circulatory
                                                    depression,
                                                    Orthostatic hypotension, Shock, Syncope (less than 5%)
                                                </li>
                                                <li><b>Endocrine metabolic:</b> Adrenal insufficiency
                                                </li>
                                                <li><b>Immunologic:</b> Anaphylaxis
                                                </li>
                                                <li><b>Musculoskeletal:</b> Myoclonus
                                                </li>
                                                <li><b>Neurologic:</b> Coma (less than 5%), Raised intracranial
                                                    pressure, Seizure (Less than
                                                    5%)
                                                </li>
                                                <li><b>Respiratory:</b> Dyspnea (3% to 10%), Respiratory depression
                                                </li>
                                                <li><b>Other:</b> Drug dependence, Drug withdrawal syndrome in neonate
                                                    of dependent mother
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>

                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#morphine-sulfatecollapseFive"
                                        role="button" aria-expanded="false"
                                        aria-controls="morphine-sulfatecollapseFive">
                                        <div class="card-header" id="morphine-sulfateheadingFive">
                                            <h1 class="card-heading">Interactions</h1>
                                        </div>
                                    </a>
                                    <div id="morphine-sulfatecollapseFive" class="collapse"
                                        aria-labelledby="morphine-sulfateheadingFive" data-parent="#morphine-sulfate">
                                        <div class="card-body">
                                            <p class="card-p">
                                                CNS depressants ( benzodiazepine....)
                                            </p>
                                        </div>
                                    </div>
                                </div>

                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#morphine-sulfatecollapseSix"
                                        role="button" aria-expanded="false" aria-controls="morphine-sulfatecollapseSix">
                                        <div class="card-header" id="morphine-sulfateheadingSix">
                                            <h1 class="card-heading">Monitoring</h1>
                                        </div>
                                    </a>
                                    <div id="morphine-sulfatecollapseSix" class="collapse"
                                        aria-labelledby="morphine-sulfateheadingSix" data-parent="#morphine-sulfate">
                                        <div class="card-body">
                                            <ul>
                                                <li> Adequate analgesia is indicative of clinical efficacy.
                                                </li>
                                                <li> Continually reassess the maintenance of pain control and the need
                                                    for continued opioid
                                                    use.
                                                </li>
                                                <li> Signs of addiction, abuse, or misuse: At baseline and regularly
                                                    thereafter
                                                </li>
                                                <li> Signs and symptoms of respiratory depression: Especially within 24
                                                    to 72 hours following
                                                    treatment initiation and after dose increases, and particularly in
                                                    high risk patients
                                                    (elderly, cachectic, and debilitated patients and those with
                                                    preexisting respiratory
                                                    depression or otherwise significantly reduced respiratory reserve)
                                                </li>
                                                <li> Signs or symptoms of respiratory depression or sedation: Patients
                                                    receiving concomitant
                                                    benzodiazepines or CNS depressants
                                                </li>
                                                <li> Signs and symptoms of sedation and respiratory depression: Patients
                                                    susceptible to the
                                                    intracranial effects of carbon dioxide retention, particularly
                                                    during initiation of therapy
                                                </li>
                                                <li> Signs and symptoms of hypotension: Ambulatory patients on
                                                    initiation and with dose
                                                    titration, especially when ability to maintain blood pressure is
                                                    compromised
                                                </li>
                                                <li> Exacerbation of biliary tract disease
                                                </li>
                                                <li> Worsened seizure control: Patients with a history of seizure
                                                    disorders
                                                </li>
                                                <li> (Epidural or intrathecal) Observe patient for a minimum of 24 hours
                                                    after each dose for
                                                    delayed respiratory depression
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>

                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#morphine-sulfatecollapseSeven"
                                        role="button" aria-expanded="false"
                                        aria-controls="morphine-sulfatecollapseSeven">
                                        <div class="card-header" id="morphine-sulfateheadingSeven">
                                            <h1 class="card-heading">Morphine Toxicity</h1>
                                        </div>
                                    </a>
                                    <div id="morphine-sulfatecollapseSeven" class="collapse"
                                        aria-labelledby="morphine-sulfateheadingSeven" data-parent="#morphine-sulfate">
                                        <div class="card-body">
                                            <p class="card-p">
                                                Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Patients may only need
                                                observation.
                                                MANAGEMENT OF SEVERE TOXICITY: Administer oxygen and assist ventilation
                                                for respiratory
                                                depression. Naloxone is the antidote indicated for severe toxicity
                                                (respiratory or CNS
                                                depression). Orotracheal intubation for airway protection should be
                                                performed early in cases
                                                of obtundation and/or respiratory depression that do not respond to
                                                naloxone, or in patients
                                                who develop severe acute lung injury.
                                            </p>
                                            <ul>
                                                <li>Antidote: NALOXONE, an opioid antagonist, is the specific antidote.
                                                    Naloxone can be given
                                                    intravascularly, intramuscularly, subcutaneously, intranasally or
                                                    endotracheally. The usual
                                                    dose is 0.4 to 2.0 mg IV. In patients with suspected opioid
                                                    dependence, incremental doses of
                                                    0.2 mg IV should be administered, titrated to reversal of
                                                    respiratory depression and coma,
                                                    to
                                                    avoid precipitating acute opioid withdrawal. Doses may be repeated
                                                    every 2 to 3 minutes up
                                                    to
                                                    20 mg. Very high doses are rarely needed
                                                </li>
                                                <li>Seizure: Seizures are rare, but may be a result of hypoxia.
                                                    Treatment includes ensuring
                                                    adequate oxygenation, and administering intravenous benzodiazepines;
                                                    propofol or
                                                    barbiturates
                                                    may be indicated, if seizures persist. Patients with seizures and
                                                    myoclonus after massive
                                                    intrathecal morphine overdose have required barbiturate coma with
                                                    continuous EEG monitoring.
                                                </li>
                                                <li>Acute lung injury: Acute lung injury can develop in a small
                                                    proportion of patients after
                                                    an
                                                    acute opioid overdose. The pathophysiology is unclear. Patients
                                                    should be observed for 4 to
                                                    6
                                                    hours after overdose to evaluate for hypoxia and/or the development
                                                    of acute lung injury.
                                                    Continuous oxygen therapy, pulse oximetry, PEEP and mechanical
                                                    ventilation may be necessary.
                                                </li>
                                                <li>Hypotensive episode: Hypotension is often reversed by naloxone.
                                                    Initially treat with a
                                                    saline bolus, if patient can tolerate a fluid load; then add
                                                    adrenergic vasopressors to
                                                    raise
                                                    mean arterial pressure if hypotension persists.
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>

                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#morphine-sulfatecollapseEight"
                                        role="button" aria-expanded="false"
                                        aria-controls="morphine-sulfatecollapseEight">
                                        <div class="card-header" id="morphine-sulfateheadingEight">
                                            <h1 class="card-heading">Cases to prescribe Morphine</h1>
                                        </div>
                                    </a>
                                    <div id="morphine-sulfatecollapseEight" class="collapse"
                                        aria-labelledby="morphine-sulfateheadingEight" data-parent="#morphine-sulfate">
                                        <div class="card-body">
                                            <ul>
                                                <li>If patient is on mechanical ventilator …. Use Fentanyl, Morphine
                                                </li>
                                                <li>If patient Extubated with Moderate to severe non-neuropathic pain
                                                    ... Use IV fentanyl,
                                                    Morphine
                                                </li>
                                                <li>If patient recieves intermittent bolus opioid dose ( Moderate pain,
                                                    Analgesia before
                                                    procedure) .. use Morphine ( long duration)
                                                </li>
                                                <li>If Oral, Transdermal opioid and ready to discharge .. Use extended
                                                    release Morphine
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>

                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="tab-pane fade" id="others" role="tabpanel" aria-labelledby="others-tab">

                <div class="mainContent">
                    <ul class="nav nav-pills mb-3" id="pills-tab-others" role="tablist">
                        <li class="nav-item">
                            <a class="nav-link active" id="pills-paracetamol-tab" data-toggle="pill"
                                href="#pills-paracetamol" role="tab" aria-controls="pills-paracetamol"
                                aria-selected="true">Acetaminophen (Paracetamol)</a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" id="pills-ketamine-tab" data-toggle="pill" href="#pills-ketamine"
                                role="tab" aria-controls="pills-ketamine" aria-selected="false">Ketamine</a>
                        </li>
                    </ul>
                    <div class="tab-content" id="pills-tab-othersContent">
                        <div class="tab-pane fade show active" id="pills-paracetamol" role="tabpanel"
                            aria-labelledby="pills-paracetamol-tab">

                            <div id="paracetamol">
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#paracetamolcollapseOne"
                                        role="button" aria-expanded="false" aria-controls="paracetamolcollapseOne">
                                        <div class="card-header" id="paracetamolheadingOne">
                                            <h1 class="card-heading">Dose</h1>
                                        </div>
                                    </a>

                                    <div id="paracetamolcollapseOne" class="collapse"
                                        aria-labelledby="paracetamolheadingOne" data-parent="#paracetamol">
                                        <div class="card-body">
                                            <p class="card-p">
                                                325 to 650 mg PO every 4 to 6 hours, as needed. Alternatively, 1,000 mg
                                                PO 2 to 4 times per
                                                day can be given. Do not exceed 1 g/dose or 4 g/day.
                                            </p>
                                            <p class="card-p">
                                                Extended Release: 650 mg to 1,300 mg PO every 8 hours as needed. Max
                                                single dose: 1,300
                                                mg/dose. Max daily dose: 3,900 mg/day.
                                            </p>
                                            <p class="card-p">
                                                IV: 1,000 mg IV every 6 hours or 650 mg IV every 4 hours as needed. Max
                                                single dose: 1,000
                                                mg/dose. Max daily dose: 4,000 mg/day.
                                            </p>
                                            <p class="card-p">
                                                15 mg/kg/dose IV every 6 hours or 12.5 mg/kg/dose IV every 4 hours as
                                                needed. Max single dose:
                                                15 mg/kg/dose or 750 mg/dose, whichever is less. Max daily dose: 75
                                                mg/kg/day or 3,750 mg/day,
                                                whichever is less
                                            </p>
                                            <p class="card-p">
                                                <ul>
                                                    <li><b>Max:</b> 4g <br>
                                                        The total daily maximum dose of 4,000 mg is the maximum dose of
                                                        acetaminophen from all
                                                        sources
                                                    </li>
                                                    <li><b>Hepatic:</b><br> Severe hepatic impairment, severe active
                                                        hepatic disease: Use is
                                                        contraindicated
                                                        Mild to moderate hepatic impairment, mild to moderate active
                                                        hepatic disease: Use with
                                                        caution; a reduced total daily dose may be warranted
                                                    </li>
                                                    <li>
                                                        <b>Renal:</b><br>CrCl &lt;= 30 mL/minute: Reduced dosing and
                                                        prolonged intervals are
                                                        recommended for IV dosing; however no quantitative
                                                        recommendations are available. For a
                                                        CrCl &lt; 10 mL/minute, administer acetaminophen (all dosage
                                                        forms) at a minimum interval
                                                        of every 8 hours. </li>
                                                </ul>
                                                Dialysis: No adjustments necessary
                                            </p>
                                        </div>
                                    </div>
                                </div>
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#paracetamolcollapseTwo"
                                        role="button" aria-expanded="false" aria-controls="paracetamolcollapseTwo">
                                        <div class="card-header" id="paracetamolheadingTwo">
                                            <h1 class="card-heading">Warnings</h1>
                                        </div>
                                    </a>
                                    <div id="paracetamolcollapseTwo" class="collapse"
                                        aria-labelledby="paracetamolheadingTwo" data-parent="#paracetamol">
                                        <div class="card-body">
                                            <ol>
                                                <li>
                                                    US BOXED WARNING: HEPATOTOXICITY: <br>
                                                    This drug has been associated with cases of acute liver failure.
                                                    Class C Liver.
                                                </li>
                                                <li>Long-term oral acetaminophen administration at a dosage of 4 g/day
                                                    has been shown to
                                                    increase international normalized ratio in some patients stabilized
                                                    on warfarin.</li>
                                            </ol>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="tab-pane fade" id="pills-ketamine" role="tabpanel"
                            aria-labelledby="pills-ketamine-tab">

                            <div id="ketamine">
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#ketaminecollapseOne"
                                        role="button" aria-expanded="false" aria-controls="ketaminecollapseOne">
                                        <div class="card-header" id="ketamineheadingOne">
                                            <h1 class="card-heading">Dose</h1>
                                        </div>
                                    </a>

                                    <div id="ketaminecollapseOne" class="collapse" aria-labelledby="ketamineheadingOne"
                                        data-parent="#ketamine">
                                        <div class="card-body">
                                            <h4>For Pain</h4>
                                            <p class="card-p">
                                                10 to 50 mg/hour IV for severe pain <br>
                                                A single dose of ketamine 0.25 mg/kg or 0.5 mg/kg was also effective for
                                                patients with cancer
                                                and neuropathic pain who were already taking morphine.
                                            </p>
                                            <ul>
                                                <li><b>Max:</b> Specific maximum dosage information is not available.
                                                    Dosage must be
                                                    individualized.</li>
                                                <li><b>Hepatic:</b> Data not available</li>
                                                <li><b>Renal:</b> Data not available</li>
                                            </ul>
                                            <h4>Dosing for mechanically ventilated adults:</h4>
                                            <p class="card-p">
                                                Iv dose initial 0.1 to 0.5 mg/kg bolus followed by 0.2 to 0.5 mg/kg/hr
                                                continuous infusion , titrate the dose to pain and/ sedation control
                                                dosing range 0.04 to 2.5 mg/kg/hr.
                                            </p>
                                        </div>
                                    </div>
                                </div>
                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#ketaminecollapseTwo"
                                        role="button" aria-expanded="false" aria-controls="ketaminecollapseTwo">
                                        <div class="card-header" id="ketamineheadingTwo">
                                            <h1 class="card-heading">Precautions</h1>
                                        </div>
                                    </a>
                                    <div id="ketaminecollapseTwo" class="collapse" aria-labelledby="ketamineheadingTwo"
                                        data-parent="#ketamine">
                                        <div class="card-body">
                                            <ol>
                                                <li>Alcoholism, ethanol intoxication :Use ketamine with caution in
                                                    patients with chronic
                                                    alcoholism or acute ethanol intoxication.</li>
                                                <li>Ketamine must be administered slowly over at least 60 seconds; more
                                                    rapid intravenous
                                                    administration can result in respiratory depression, apnea, and
                                                    enhanced pressor response.
                                                </li>
                                                <li>Because ketamine can cause psychosis and exacerbate symptoms of
                                                    chronic schizophrenics, it
                                                    should be used with caution in patients with psychiatric disorders,
                                                    such as schizophrenia or
                                                    acute psychosis</li>
                                                <li>Vomiting has been reported following ketamine administration. Intact
                                                    laryngeal-pharyngeal
                                                    reflexes may offer some protection, however the possibility of
                                                    aspiration must be considered
                                                    due to the use of supplemental anesthetics and muscle relaxants.
                                                </li>
                                            </ol>
                                        </div>
                                    </div>
                                </div>

                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#ketaminecollapseThree"
                                        role="button" aria-expanded="false" aria-controls="ketaminecollapseThree">
                                        <div class="card-header" id="ketamineheadingThree">
                                            <h1 class="card-heading">Contraindications</h1>
                                        </div>
                                    </a>
                                    <div id="ketaminecollapseThree" class="collapse"
                                        aria-labelledby="ketamineheadingThree" data-parent="#ketamine">
                                        <div class="card-body">
                                            <ul>
                                                <li>
                                                    Ketamine is contraindicated in patients in whom a significant
                                                    elevation of blood pressure
                                                    would constitute a serious hazard, such as those patients with
                                                    hypertension, stroke, head
                                                    trauma or intracranial mass, or intracranial bleeding. Similarly,
                                                    ketamine should be used
                                                    with caution in patients with increased intracranial pressure or
                                                    increased intraocular
                                                    pressure (e.g., glaucoma) because these pressures may increase
                                                    significantly after a
                                                    single dose of ketamine.
                                                </li>
                                                <li>
                                                    Use ketamine with caution in patients with a history of
                                                    thyrotoxicosis because they are at
                                                    an increased risk of developing tachycardia and hypertension due to
                                                    ketamine-induced
                                                    cardiac stimulation.
                                                </li>
                                            </ul>

                                        </div>
                                    </div>
                                </div>

                                <div class="card">
                                    <a class="collapsed" data-toggle="collapse" href="#ketaminecollapseFour"
                                        role="button" aria-expanded="false" aria-controls="ketaminecollapseFour">
                                        <div class="card-header" id="ketamineheadingFour">
                                            <h1 class="card-heading">Interactions</h1>
                                        </div>
                                    </a>
                                    <div id="ketaminecollapseFour" class="collapse"
                                        aria-labelledby="ketamineheadingFour" data-parent="#ketamine">
                                        <div class="card-body">
                                            <p class="card-p">
                                                The use of ketamine with other CNS depressants, including opiate
                                                agonists, potentiate CNS
                                                depression and/or increase the risk of developing respiratory
                                                depression.
                                            </p>
                                        </div>
                                    </div>
                                </div>

                            </div>
                        </div>
                    </div>
                </div>

            </div>
        </div>

    </div>





</div>